beta-D-Ribofuranose 1-Acetate 2,3,5-Tribenzoate>98.0%(HPLC)25g

Monohidrato de ácido orótico, mínimo 99%, 50 g, envase de plástico.

tert-Butyl 4-(6-((6-bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carboxylate, 98%, 5g

4-Vinyl-1,3-dioxolan-2-one, 95.0%, 25g

3-(2-Naphthyl)-L-alanine>97.0%(T)1g

ethyl N-cyclopropylglycinate, 95.0%, 1g

6-Bromo-2-fluoro-3-methylbenzonitrile, 97%, 10g

(Z)-Methyl 3-(((4-acetamidophenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate (Nintedanib Impurity), 97%, 50mg

5-(AMINOMETHYL)PYRIDIN-3-AMINE 2HCL, 95.0%, 1g

tert-Butyl 2-chloro-5-methoxybenzoate, 98%, 10g

2-Amino-6-chlorobenzonitrile, 98.0%, 25g

5,7-Dichloro-1H-pyrazolo[4,3-d]pyrimidine, 95.0%, 250mg

2,6-Di-tert-butyl-4-methylcyclohexan-1-one, 98%, 250mg